Devyser secures SEK 8.9M five-year tender and strengthens Italian position
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
This paper by Dr. Agneta Wikman, Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
This paper by Dr. Agneta Wikman, Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
Read More
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More